Preventing EBV reactivation with rituximab after stem cell transplant in children
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a child scheduled for a stem cell transplant from a half-matched family donor.
- Your doctor plans to use a conditioning regimen that includes ATG (anti-thymocyte globulin).
- You must not have had an active EBV infection or EBV-related blood disorder before transplant.
- You must not have used certain B-cell depleting drugs (like rituximab) in the two weeks before transplant.
- You must have a good performance status (able to carry on daily activities) as judged by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests whether giving rituximab early after a stem cell transplant can prevent a common viral infection (EBV) from becoming serious. It may help reduce complications and improve recovery.
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
This trial tests whether a drug called rituximab can prevent a type of cancer called PTLD in people who have had an organ transplant and are showing signs of an EBV infection. EBV is a common virus that can be more dangerous for transplant patients, and this study aims to see if using rituximab early can stop PTLD from developing.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Hear when a new EBV Infection After Allogenic HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.